Core Viewpoint - The company has completed the convertible bond fundraising project and plans to permanently supplement its working capital with the remaining funds of 60,787,077.87 yuan, which includes cash management income and interest [1][4][6]. Summary by Sections Fundraising Project Completion - The company held a board meeting on July 3, 2025, to approve the conclusion of the convertible bond fundraising project, which has reached its intended operational status [1][7]. - The total amount raised through the convertible bonds was 285 million yuan, with a net amount of 279.79889 million yuan after deducting issuance costs [2][4]. Fund Management and Usage - A special account was established for the management of the raised funds, and a tripartite supervision agreement was signed with relevant parties [3][5]. - As of July 3, 2025, the remaining funds in the special account amounted to 60,787,077.87 yuan, representing 21.73% of the total raised funds [4][5]. Reasons for Fund Surplus - The surplus funds resulted from careful resource allocation and cost control during the project, as well as reduced material and funding needs due to a decline in factory order volumes [5][6]. - The company also achieved cash management income from idle funds, enhancing the efficiency of fund usage [5][6]. Future Use of Surplus Funds - The company intends to use the surplus funds to permanently supplement its working capital, which will support ongoing and future business operations [6][7]. - The decision to use the surplus funds does not alter the intended use of the raised funds and complies with relevant regulations [6][7]. Approval Process - The board's audit committee reviewed and approved the proposal to conclude the fundraising project and use the surplus funds, which will be submitted for shareholder approval [6][7][8].

三生国健: 三生国健：关于公司2024年度募集资金存放与实际使用情况的专项 报告 证券代码：688336 证券简称：三生国健 公告编号：2025-012 三生国健药业（上海）股份有限公司 关于公司 2024 年度募集资金存放与实际使用情况的 专项报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 根据《上市公司监管指引第 2 号——上市公司募集资金管理和使 用的监管要求》、《上海证券交易所科创板上市公司自律监管指引第 关规定，三生国健药业（上海）股份有限公司（以下简称"公司"或 "本公司"）董事会对 2024 年度募集资金存放与实际使用情况专项 报告说明如下： 一、募集资金基本情况 （一）实际募集资金的金额及到账时间 公司经上海证券交易所科创板股票上市委员会 2020 年 5 月 11 日 审核同意，并经中国证券监督管理委员会 2020 年 6 月 23 日《关于同 意三生国健药业（上海）股份有限公司首次公开发行股票注册的批复》 （证监许可20201217 号）注册同意，首次公开发行人民币普通股 （A 股）股票 61,6 ...